Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel
NASDAQ:NCNA

NuCana Q4 2024 Earnings Report

NuCana logo
$1.34 +0.10 (+8.06%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$1.40 +0.06 (+4.48%)
As of 07/10/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

NuCana EPS Results

Actual EPS
-$64.00
Consensus EPS
-$486.00
Beat/Miss
Beat by +$422.00
One Year Ago EPS
N/A

NuCana Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

NuCana Announcement Details

Quarter
Q4 2024
Date
3/20/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

NuCana's next earnings date is estimated for Thursday, August 13, 2026, based on past reporting schedules.

Conference Call Resources

NuCana Earnings Headlines

NuCana plc Sponsored ADR
June 16, 2026  |  edition.cnn.comhttps://edition.cnn.com/markets/stocks/NCNA
NuCana Appoints Ian Webster as Chief Financial Officer
June 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/01/3304314/0/en/nucana-appoints-ian-webster-as-chief-financial-officer.html
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
July 11 at 1:00 AM  |  Stansberry Research (Ad)
NuCana Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3295318/0/en/nucana-reports-first-quarter-2026-financial-results-and-provides-business-update.html
NuCana Posts 2025 Results, Highlights NUC-7738 Progress and Cash Runway Into 2029
March 22, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/871927/nucana-posts-2025-results-highlights-nuc-7738-progress-and-cash-runway-into-2029/
NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update
March 19, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/19/3259416/0/en/nucana-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-business-update.html
See More NuCana Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NuCana? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NuCana and other key companies, straight to your email.

About NuCana

NuCana (NASDAQ:NCNA) plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure. NUC-3373 is being evaluated in multiple Phase 2 studies, including trials in colorectal and gastric cancers. In addition to NUC-3373, the company is advancing NUC-7738, an innate immune response modulator, through early-stage clinical development. These programs exemplify NuCana’s strategy of applying its ProTide chemistry to diversify treatment options for oncology patients.

Founded in 2013, NuCana has grown from a UK-based research startup into a globally oriented organization with clinical operations and collaborations across North America and Europe. Under the leadership of Chief Executive Officer Alastair Smith, the company continues to expand its clinical footprint, engaging with academic institutions and industry partners to accelerate the development and potential commercialization of its drug candidates. NuCana remains committed to translating its proprietary chemistry platform into differentiated therapies that address unmet medical needs in cancer care.

View NuCana Profile
Earnings Tools